September 21, 2023 7:40am

I’m occasionally retelling “Romeo and Juliet” about our sector, the question is; who are the sellers or when should buyers purchase downtrodden equities. “Deny thy pricing and refuse thy orders or if thou wilt not be but sworn”

Pre-open Indications: 1 Positive and 1 Negative Indication

News: Vericel (VCEL +$0.48 pre-open) with the U.S. commercial availability of NexoBrid® (anacaulase-bcdb) for the removal of eschar in adults with deep partial- and/or full-thickness thermal burns. Eschar removal is a critical first step in the treatment of burns as it can reduce inflammation, stop burn progression, as well as mitigate infections and sepsis.

It’s an honor to be considered the “canary in the (sectors) coal mine”!  I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors in the perception of sector vulnerabilities and strengths – it’s more than opinion, the facts and truth need to be recognized!

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors! 

8:00 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on what will happen behind the headlines today, not tomorrow or yesterday

 

Dow futures are DOWN -0.54% or (-188 points), S&P futures are DOWN -0.78% or (-34 points) and NASDAQ futures are DOWN -1.04% or (-157 points) early in the pre-open – so far

Stock futures fell Thursday with worries over future Fed rate increases,

European markets were lower amid a raft of interest rate decisions from central banks in England, Turkey, Sweden, Switzerland and Norway,

Asia-Pacific markets fell across the region.

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes declined on Wednesday morning as the fed reported a no-go policy shift, as the Dow closed DOWN -76.85 points or -0.22%, the S&P closed DOWN -41.75 points or -0.94% while the Nasdaq closed DOWN -209.06 points or -1.53%.

Economic Data Docket: weekly jobless claims due before the opening bell, as well as existing home sales data out later in morning.

 

Wednesday’s (9/20) RegMed Investors’ (RMi) closing bell: “sector equities oscillated deeper as Fed declines to hike. Sentiment is defined as attitude and bias or opinion as it rolled through its daily and weekly to date characterizations of the cell and gene therapy sector.”  … https://www.regmedinvestors.com/articles/13129

 

Ebb and flow:

Q3: September – 1 holiday, 6 positive and 7 negative closes

·         August – 9 positive and 14 negative closes

·         July - 1 holiday, 12 positive and 8 negative close

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

 

Negative Indications:

Wednesday’s closing price, some Tuesday and Monday closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Ultragenyx Pharmaceuticals (RARE) closed down -$0.21, Tuesday’s +$0.08 and Monday’s -$1.37 with a negative -$0.72 or -1.99% aftermarket indication.

 

Positive indications:

Wednesday’s closing price, some Tuesday and Monday closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Vericel (VCEL) closed down -$5.15 after Tuesday’s -$0.28 with a positive +$0.48 or +1.48% aftermarket indication on news of NexoBrid availability that selectively targets eschar while preserving viable tissue, enabling more rapid and precise eschar removal, which may reduce the need for subsequent skin grafting and lessen patient trauma.

 

The BOTTOM LINE: underlines the framework of share pricing actions...

A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.

The cell and gene therapy closed down on Wednesday, Tuesday, Monday and last Friday but was weak for the previous Thursday “ascension” while exhibiting shallow upsides.

This and some of last week: a maybe NOT upswing for Thursday but it’s coming as …

·         Wednesday closed negative with 3 incliners, 31 decliners and 1 flat

·         Tuesday closed negative with 17 incliners, 18 decliners and 0 flats

·         Monday closed negative with 11 incliners, 22 decliners and 2 flats

·         Friday closed negative with 8 incliners, 25 decliners and 2 flats

·         Thursday closed positive with 18 incliners, 15 decliners and 2 flats

·         Last Wednesday closed negative with 7 incliners, 24 decliners and 4 flats

Did “uncle algo” and his electronic trading dwarfs coming to visit?

 

The remainder of the month’s trading sessions will be critical for the RegMed, cell and gene therapy sector which will establish whether market reaction to recent events is temporary and short-lived or there will be further fundamental correction. 

 

Where and when is value creation as we slip further into September and the end of Q3 with LPS <loss-per-share> quarterly releases coming due?  

I believe a number of decliners need to be bought, a few sold into strength and a number of negative indications document a continued sell.

I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!

There's ALSO nothing wrong with standing pat in the short run, holding on to sizable existing exposure.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.